Markets:

Overview

News

Currencies

International

Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.530 +0.440 (+8.64%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 08, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ALDEYRA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm

August 08, 2023

From Bragar Eagel & Squire, P.C.,

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aldeyra Therapeutics, Inc. (ALDX) Investors

August 07, 2023

From Law Offices of Howard G. Smith

Via Business Wire

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

August 06, 2023

Via ACCESSWIRE

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDX

August 04, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

August 03, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

August 03, 2023

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors

August 03, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDX

August 02, 2023

From Rosen Law Firm

Via Business Wire

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Aldeyra Therapeutics, Inc. (ALDX)

August 01, 2023

From Robbins LLP

Via Business Wire

Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum

July 06, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa

June 29, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa

June 28, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough

June 27, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough

June 26, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

June 23, 2023

From Aldeyra Therapeutics

Via Business Wire

Aldeyra Therapeutics Provides Regulatory Update on ADX-2191

June 21, 2023

From Aldeyra Therapeutics

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis

June 14, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

June 02, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights

May 04, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

May 02, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

Via FinancialNewsMedia

Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis

April 13, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) Records 52-Week High Monday Morning

April 10, 2023

Via Investor Brand Network

Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis

April 06, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough

March 30, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa

March 16, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

March 09, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma

March 02, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights

March 01, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease

February 28, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

Press Releases about Aldeyra Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today